UK government announces £400m innovation fund


The UK government’s Technology Strategy Board (TSB) has set aside £400 million to help companies commercialise new technologies in the 2014–15 financial year.

The TSB, which was set up in 2007 to create economic growth by supporting innovation in UK businesses, has released its delivery plan for 2014–2015, which includes £400 million that will be made available to companies through competitions. The cash will be divided up between priority areas such as healthcare, energy and transport.

The TSB also plans to focus more on supporting small and medium enterprises (SMEs), and has said it will increase financial support available to these by £10 million this year. In addition, two new Catapult centres – in precision medicine and energy systems – will join the seven already established, and a third, which is slated to focus on replacing animals in research, is being considered.


Related Content

Horizon 2020 - New European funding for research and innovation

13 February 2014 Webinars

news image

Find out how you can engage with the Horizon 2020 European funding programme

The hunt for innovation

31 January 2014 Premium contentFeature

news image

Big pharma companies are embracing a more open and collaborative approach. Nuala Moran discovers who’s working with whom

Most Read

Complex amines made easy (and cheap)

22 May 2015 Research

news image

Iron-catalysed cross-coupling brings together nitroarenes and olefins in a single step in boon for drug makers

Opiate-producing yeast raises spectre of 'home-brewed heroin'

18 May 2015 News and Analysis

news image

Warnings that completion of final steps in opiate biosynthesis could be a double-edged sword

Most Commented

The nuclear danger of iodine

20 May 2015 Comments

news image

It may not be an element you think of as problematic. But, as Mark Foreman explains, iodine causes very complicated problems ...

Opiate-producing yeast raises spectre of 'home-brewed heroin'

18 May 2015 News and Analysis

news image

Warnings that completion of final steps in opiate biosynthesis could be a double-edged sword